Interferon alfa
- Generic Name
- Interferon alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Natural interferon alpha or Multiferon is obtained from the leukocyte fraction of human blood following induction with Sendai virus. Interferon alfa contains several naturally occurring IFN-α subtypes and is purified by affinity chromatography. Interferon alpha proteins are mainly involved in innate immune response against viral infection. They come in 13 su...
- Indication
Investigated for use/treatment in hepatitis (viral, C), leukemia (lymphoid), leukemia (myeloid), leukemia (unspecified), and melanoma.
- Associated Conditions
- Follicular Non-Hodgkin's Lymphoma, Hematological Malignancy, Hepatitis C Virus (HCV) Infection, Malignant Melanoma, Renal Cell Carcinoma (RCC), Viral Hepatitis B
- Associated Therapies
- -
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06130579
- Locations
- 🇨🇳
Deparment of Hematology, Peking University People's Hospital, Beijing, Beijing, China
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
- Conditions
- Interventions
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 441
- Registration Number
- NCT04534725
- Locations
- 🇦🇺
St Vincent's Hospital, Fitzroy, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Melbourne, Victoria, Australia
Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis
- Conditions
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2006-02-16
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 456
- Registration Number
- NCT00291369
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2003-07-25
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 626
- Registration Number
- NCT00065468
- Locations
Pfizer Investigational Site
Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 57
- Registration Number
- NCT00004804
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.